Definium Therapeutics, Inc. (MNMD)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $397k
- Sep 25 · Routine
- Form 4 sales
- 72
- On record
- Form 144 notices
- 48
- Proposed sales
- Sold, last 30 days
- None
- No Form 4 sale
- Sold, last 90 days
- $3M
- 6 sales by 5 insiders
- 0.06% of shares outstanding
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- Sep 25, 2026Routine
Daniel Karlin, Chief Medical Officer, sold 1.4% of their holdings
$397k10,853 shares at $36.57
- Sep 25, 2026Routine
Robert Barrow, Chief Executive Officer, sold 1.4% of their holdings
$1.2M31,550 shares at $36.57
- Sep 25, 2026Routine
Matthew T. Wiley, Chief Commercial Officer, sold 0.9% of their holdings
$113k3,097 shares at $36.57
- Sep 25, 2026Routine
Mark Sullivan, Chief Legal Officer, sold 2.8% of their holdings
$514k14,051 shares at $36.57
- Sep 25, 2026Routine
Brandi Roberts, Chief Financial Officer, sold 0.8% of their holdings
$123k3,377 shares at $36.57
- Sep 25, 2026Notice
Mark Sullivan, Chief Legal Officer, filed a notice to sell 14,051 shares
$516k14,051 shares
- Sep 25, 2026Notice
Brandi Roberts, Chief Financial Officer, filed a notice to sell 3,377 shares
$124k3,377 shares
- Sep 25, 2026Notice
Matthew T. Wiley, Chief Commercial Officer, filed a notice to sell 3,097 shares
$114k3,097 shares
- Sep 25, 2026Notice
Daniel Karlin, Chief Medical Officer, filed a notice to sell 10,853 shares
$399k10,853 shares
- Sep 25, 2026Notice
Robert Barrow, Chief Executive Officer, filed a notice to sell 31,550 shares
$1.2M31,550 shares
Every transaction
| Traded | Filed | Stock | Name | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Sep 29, 2026 | MNMD | Daniel Karlin | Chief Medical Officer | Sold | 10,853 | $36.57 | $397k | 792,846 | SEC |
| Sep 25, 2026 | Sep 29, 2026 | MNMD | Robert Barrow | Chief Executive Officer | Sold | 31,550 | $36.57 | $1.2M | 2.2M | SEC |
| Sep 25, 2026 | Sep 29, 2026 | MNMD | Matthew T. Wiley | Chief Commercial Officer | Sold | 3,097 | $36.57 | $113k | 359,036 | SEC |
| Sep 25, 2026 | Sep 29, 2026 | MNMD | Mark Sullivan | Chief Legal Officer | Sold | 14,051 | $36.57 | $514k | 494,228 | SEC |
| Sep 25, 2026 | Sep 29, 2026 | MNMD | Brandi Roberts | Chief Financial Officer | Sold | 3,377 | $36.57 | $123k | 394,528 | SEC |
| Sep 18, 2026 | Sep 18, 2026 | MNMD | Andreas Krebs | Director | Exercised or settledStock Option (Right to Buy) | 1,629 | 0 | SEC | ||
| Sep 18, 2026 | Sep 18, 2026 | MNMD | Andreas Krebs | Director | Exercised options | 1,629 | $35.52 | $58k | 21,402 | SEC |
| Sep 18, 2026 | Sep 18, 2026 | MNMD | Carol A Vallone | Director | Exercised or settledStock Option (Right to Buy) | 1,086 | 0 | SEC | ||
| Sep 18, 2026 | Sep 18, 2026 | MNMD | Carol A Vallone | Director | Exercised options | 1,086 | $35.52 | $39k | 22,296 | SEC |
| Sep 14, 2026 | Sep 14, 2026 | MNMD | Daniel Karlin | Chief Medical Officer | Awarded | 200,000 | 803,699 | SEC | ||
| Sep 14, 2026 | Sep 14, 2026 | MNMD | Matthew T. Wiley | Chief Commercial Officer | Awarded | 125,000 | 362,133 | SEC | ||
| Sep 14, 2026 | Sep 14, 2026 | MNMD | Mark Sullivan | Chief Legal Officer | Awarded | 125,000 | 508,279 | SEC | ||
| Sep 14, 2026 | Sep 14, 2026 | MNMD | Brandi Roberts | Chief Financial Officer | Awarded | 125,000 | 397,905 | SEC | ||
| Sep 14, 2026 | Sep 14, 2026 | MNMD | Robert Barrow | Chief Executive Officer | Awarded | 750,000 | 2.2M | SEC | ||
| Sep 3, 2026 | Sep 4, 2026 | MNMD | Robert Barrow | Chief Executive Officer | Sold | 19,023 | $37.94 | $722k | 1.5M | SEC |
| Sep 2, 2026 | Sep 4, 2026 | MNMD | Robert Barrow | Chief Executive Officer | Awarded | 40,000 | 1.5M | SEC | ||
| Aug 12, 2026 | Aug 12, 2026 | MNMD | Robert Barrow | Chief Executive Officer | Awarded | 375,000 | 1.5M | SEC | ||
| Aug 12, 2026 | Aug 12, 2026 | MNMD | Daniel Karlin | Chief Medical Officer | Awarded | 100,000 | 603,282 | SEC | ||
| Aug 12, 2026 | Aug 12, 2026 | MNMD | Mark Sullivan | Chief Legal Officer | Awarded | 62,500 | 383,071 | SEC | ||
| Aug 12, 2026 | Aug 12, 2026 | MNMD | Matthew T. Wiley | Chief Commercial Officer | Awarded | 62,500 | 237,133 | SEC | ||
| Aug 12, 2026 | Aug 12, 2026 | MNMD | Brandi Roberts | Chief Financial Officer | Awarded | 62,500 | 271,987 | SEC | ||
| Jun 25, 2026 | Jun 26, 2026 | MNMD | Mark Sullivan | Chief Legal Officer | Sold | 13,008 | $45.03 | $586k | 320,571 | SEC |
| Jun 25, 2026 | Jun 26, 2026 | MNMD | Daniel Karlin | Chief Medical Officer | Sold | 10,035 | $45.03 | $452k | 503,282 | SEC |
| Jun 25, 2026 | Jun 26, 2026 | MNMD | Brandi Roberts | Chief Financial Officer | Sold | 3,013 | $45.03 | $136k | 209,487 | SEC |
| Jun 25, 2026 | Jun 26, 2026 | MNMD | Robert Barrow | Chief Executive Officer | Sold | 29,208 | $45.03 | $1.3M | 1.1M | SEC |
| Jun 25, 2026 | Jun 26, 2026 | MNMD | Matthew T. Wiley | Chief Commercial Officer | Sold | 2,867 | $45.03 | $129k | 174,633 | SEC |
| Jun 22, 2026 | Jun 22, 2026 | MNMD | Robert Barrow | Chief Executive Officer | Awarded | 375,000 | 1.1M | SEC | ||
| Jun 22, 2026 | Jun 22, 2026 | MNMD | Matthew T. Wiley | Chief Commercial Officer | Awarded | 62,500 | 177,500 | SEC | ||
| Jun 22, 2026 | Jun 22, 2026 | MNMD | Brandi Roberts | Chief Financial Officer | Awarded | 62,500 | 212,500 | SEC | ||
| Jun 22, 2026 | Jun 22, 2026 | MNMD | Mark Sullivan | Chief Legal Officer | Awarded | 62,500 | 333,579 | SEC | ||
| Jun 22, 2026 | Jun 22, 2026 | MNMD | Daniel Karlin | Chief Medical Officer | Awarded | 100,000 | 513,317 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Roger Crystal | Director | AwardedStock Option (Right to Buy) | 19,188 | 19,188 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Roger Crystal | Director | Awarded | 4,666 | 24,289 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | David W Gryska | Director | AwardedStock Option (Right to Buy) | 19,188 | 19,188 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | David W Gryska | Director | Awarded | 4,666 | 19,900 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Carol A Vallone | Director | AwardedStock Option (Right to Buy) | 19,188 | 19,188 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Carol A Vallone | Director | Awarded | 4,666 | 21,210 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Andreas Krebs | Director | AwardedStock Option (Right to Buy) | 19,188 | 19,188 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Andreas Krebs | Director | Awarded | 4,666 | 19,773 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Roger Adsett | Director | AwardedStock Option (Right to Buy) | 14,620 | 14,620 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Roger Adsett | Director | Awarded | 3,555 | 3,555 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Suzanne Louise Bruhn | Director | AwardedStock Option (Right to Buy) | 19,188 | 19,188 | SEC | ||
| Jun 11, 2026 | Jun 15, 2026 | MNMD | Suzanne Louise Bruhn | Director | Awarded | 4,666 | 24,289 | SEC | ||
| Mar 25, 2026 | Mar 26, 2026 | MNMD | Daniel Karlin | Chief Medical Officer | Sold | 8,018 | $18.47 | $148k | 413,317 | SEC |
| Mar 25, 2026 | Mar 26, 2026 | MNMD | Mark Sullivan | Chief Legal Officer | Sold | 10,702 | $18.47 | $198k | 271,079 | SEC |
| Mar 25, 2026 | Mar 26, 2026 | MNMD | Robert Barrow | Chief Executive Officer | Sold | 24,431 | $18.47 | $451k | 752,454 | SEC |
| Feb 3, 2026 | Feb 5, 2026 | MNMD | Matthew T. Wiley | Chief Commercial Officer | Awarded | 115,000 | 115,000 | SEC | ||
| Feb 3, 2026 | Feb 5, 2026 | MNMD | Brandi Roberts | Chief Financial Officer | Awarded | 150,000 | 150,000 | SEC | ||
| Feb 3, 2026 | Feb 5, 2026 | MNMD | Mark Sullivan | Chief Legal Officer | Awarded | 125,000 | 407,576 | SEC | ||
| Feb 3, 2026 | Feb 5, 2026 | MNMD | Daniel Karlin | Chief Medical Officer | Awarded | 150,000 | 575,025 | SEC |
Sales, notices and lockups (120)
Export watchlist as CSV| Source | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Sep 29, 2026 | Daniel Karlin | MNMD | Chief Medical Officer | Form 4 sale | 10,853 | $397k | 1.4% | Routine | SEC |
| Sep 25, 2026 | Sep 29, 2026 | Robert Barrow | MNMD | Chief Executive Officer | Form 4 sale | 31,550 | $1.2M | 1.4% | Routine | SEC |
| Sep 25, 2026 | Sep 29, 2026 | Matthew T. Wiley | MNMD | Chief Commercial Officer | Form 4 sale | 3,097 | $113k | 0.9% | Routine | SEC |
| Sep 25, 2026 | Sep 29, 2026 | Mark Sullivan | MNMD | Chief Legal Officer | Form 4 sale | 14,051 | $514k | 2.8% | Routine | SEC |
| Sep 25, 2026 | Sep 29, 2026 | Brandi Roberts | MNMD | Chief Financial Officer | Form 4 sale | 3,377 | $123k | 0.8% | Routine | SEC |
| Sep 25, 2026 | Sep 25, 2026 | Mark Sullivan | MNMD | Chief Legal Officer | Form 144 notice | 14,051 | $516k | Notice | SEC | |
| Sep 25, 2026 | Sep 25, 2026 | Brandi Roberts | MNMD | Chief Financial Officer | Form 144 notice | 3,377 | $124k | Notice | SEC | |
| Sep 25, 2026 | Sep 25, 2026 | Matthew T. Wiley | MNMD | Chief Commercial Officer | Form 144 notice | 3,097 | $114k | Notice | SEC | |
| Sep 25, 2026 | Sep 25, 2026 | Daniel Karlin | MNMD | Chief Medical Officer | Form 144 notice | 10,853 | $399k | Notice | SEC | |
| Sep 25, 2026 | Sep 25, 2026 | Robert Barrow | MNMD | Chief Executive Officer | Form 144 notice | 31,550 | $1.2M | Notice | SEC | |
| Sep 3, 2026 | Sep 4, 2026 | Robert Barrow | MNMD | Chief Executive Officer | Form 4 sale | 19,023 | $722k | 1.3% | Routine | SEC |
| Sep 3, 2026 | Sep 3, 2026 | Robert Barrow | MNMD | Chief Executive Officer | Form 144 notice | 19,023 | $718k | Notice | SEC | |
| Jun 25, 2026 | Jun 26, 2026 | Mark Sullivan | MNMD | Chief Legal Officer | Form 4 sale | 13,008 | $586k | 3.9% | Routine | SEC |
| Jun 25, 2026 | Jun 26, 2026 | Daniel Karlin | MNMD | Chief Medical Officer | Form 4 sale | 10,035 | $452k | 2.0% | Routine | SEC |
| Jun 25, 2026 | Jun 26, 2026 | Brandi Roberts | MNMD | Chief Financial Officer | Form 4 sale | 3,013 | $136k | 1.4% | Routine | SEC |
| Jun 25, 2026 | Jun 26, 2026 | Robert Barrow | MNMD | Chief Executive Officer | Form 4 sale | 29,208 | $1.3M | 2.6% | Routine | SEC |
| Jun 25, 2026 | Jun 26, 2026 | Matthew T. Wiley | MNMD | Chief Commercial Officer | Form 4 sale | 2,867 | $129k | 1.6% | Routine | SEC |
| Jun 25, 2026 | Jun 25, 2026 | Mark Sullivan | MNMD | Chief Legal Officer | Form 144 notice | 13,008 | $548k | Notice | SEC | |
| Jun 25, 2026 | Jun 25, 2026 | Matthew T. Wiley | MNMD | Chief Commercial Officer | Form 144 notice | 2,867 | $121k | Notice | SEC | |
| Jun 25, 2026 | Jun 25, 2026 | Brandi Roberts | MNMD | Chief Financial Officer | Form 144 notice | 3,013 | $127k | Notice | SEC | |
| Jun 25, 2026 | Jun 25, 2026 | Daniel Karlin | MNMD | Chief Medical Officer | Form 144 notice | 10,035 | $423k | Notice | SEC | |
| Jun 25, 2026 | Jun 25, 2026 | Robert Barrow | MNMD | Chief Executive Officer | Form 144 notice | 29,208 | $1.2M | Notice | SEC | |
| Mar 25, 2026 | Mar 26, 2026 | Daniel Karlin | MNMD | Chief Medical Officer | Form 4 sale | 8,018 | $148k | 1.9% | Routine | SEC |
| Mar 25, 2026 | Mar 26, 2026 | Mark Sullivan | MNMD | Chief Legal Officer | Form 4 sale | 10,702 | $198k | 3.8% | Routine | SEC |
| Mar 25, 2026 | Mar 26, 2026 | Robert Barrow | MNMD | Chief Executive Officer | Form 4 sale | 24,431 | $451k | 3.1% | Routine | SEC |
| Mar 25, 2026 | Mar 25, 2026 | Robert Barrow | MNMD | Chief Executive Officer | Form 144 notice | 24,431 | $451k | Notice | SEC | |
| Mar 25, 2026 | Mar 25, 2026 | Daniel Karlin | MNMD | Chief Medical Officer | Form 144 notice | 8,018 | $148k | Notice | SEC | |
| Mar 25, 2026 | Mar 25, 2026 | Mark Sullivan | MNMD | Chief Legal Officer | Form 144 notice | 10,702 | $198k | Notice | SEC | |
| Dec 29, 2025 | Dec 29, 2025 | Daniel Karlin | MNMD | Chief Medical Officer | Form 144 notice | 5,600 | $74k | Notice | SEC | |
| Dec 29, 2025 | Dec 29, 2025 | Mark Sullivan | MNMD | Chief Legal Officer | Form 144 notice | 11,276 | $148k | Notice | SEC | |
| Dec 29, 2025 | Dec 29, 2025 | Robert Barrow | MNMD | Chief Executive Officer | Form 144 notice | 25,791 | $339k | Notice | SEC | |
| Dec 26, 2025 | Dec 29, 2025 | Daniel Karlin | MNMD | Chief Medical Officer | Form 4 sale | 5,600 | $74k | 1.3% | Routine | SEC |
| Dec 26, 2025 | Dec 29, 2025 | Robert Barrow | MNMD | Chief Executive Officer | Form 4 sale | 25,791 | $339k | 3.2% | Routine | SEC |
| Dec 26, 2025 | Dec 29, 2025 | Mark Sullivan | MNMD | Chief Legal Officer | Form 4 sale | 11,276 | $148k | 3.8% | Routine | SEC |
| Sep 25, 2025 | Sep 26, 2025 | Mark Sullivan | MNMD | Chief Legal Officer | Form 4 sale | 11,278 | $110k | 3.7% | Routine | SEC |
| Sep 25, 2025 | Sep 26, 2025 | Robert Barrow | MNMD | Chief Executive Officer | Form 4 sale | 25,797 | $252k | 3.1% | Routine | SEC |
| Sep 25, 2025 | Sep 26, 2025 | Daniel Karlin | MNMD | Chief Medical Officer | Form 4 sale | 7,704 | $75k | 1.8% | Routine | SEC |
| Sep 25, 2025 | Sep 25, 2025 | Mark Sullivan | MNMD | Chief Legal Officer | Form 144 notice | 11,278 | $110k | Notice | SEC | |
| Sep 25, 2025 | Sep 25, 2025 | Daniel Karlin | MNMD | Chief Medical Officer | Form 144 notice | 7,704 | $75k | Notice | SEC | |
| Sep 25, 2025 | Sep 25, 2025 | Robert Barrow | MNMD | Chief Executive Officer | Form 144 notice | 25,797 | $252k | Notice | SEC | |
| Jun 25, 2025 | Jun 26, 2025 | Mark Sullivan | MNMD | Chief Legal Officer | Form 4 sale | 11,491 | $78k | 3.6% | Routine | SEC |
| Jun 25, 2025 | Jun 26, 2025 | Daniel Karlin | MNMD | Chief Medical Officer | Form 4 sale | 7,848 | $53k | 1.8% | Routine | SEC |
| Jun 25, 2025 | Jun 26, 2025 | Robert Barrow | MNMD | Chief Executive Officer | Form 4 sale | 26,491 | $180k | 3.1% | Routine | SEC |
| Jun 25, 2025 | Jun 25, 2025 | Daniel Karlin | MNMD | Chief Medical Officer | Form 144 notice | 7,848 | $53k | Notice | SEC | |
| Jun 25, 2025 | Jun 25, 2025 | Mark Sullivan | MNMD | Chief Legal Officer | Form 144 notice | 11,491 | $78k | Notice | SEC | |
| Jun 25, 2025 | Jun 25, 2025 | Robert Barrow | MNMD | Chief Executive Officer | Form 144 notice | 26,491 | $180k | Notice | SEC | |
| Mar 25, 2025 | Mar 26, 2025 | Robert Barrow | MNMD | Chief Executive Officer | Form 4 sale | 21,208 | $143k | 2.4% | Routine | SEC |
| Mar 25, 2025 | Mar 26, 2025 | Daniel Karlin | MNMD | Chief Medical Officer | Form 4 sale | 6,836 | $46k | 1.5% | Routine | SEC |
| Mar 25, 2025 | Mar 26, 2025 | Mark Sullivan | MNMD | Chief Legal Officer | Form 4 sale | 6,576 | $44k | 2.0% | Routine | SEC |
| Mar 25, 2025 | Mar 26, 2025 | Carrie Liao | MNMD | Chief Accounting Officer | Form 4 sale | 2,347 | $16k | 1.6% | Routine | SEC |